Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-week randomized double-blind placebo-controlled study of PPM-204 in treatment-naive type 2 diabetes mellitus
2005-004227-19Phase 2Completed
- Sponsor
- Wyeth
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Indeglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Wyeth. Primary endpoints: Change from baseline in fasting plasma glucose at day 28, Change from baseline in mean plasma glucose during OGTT at day 28 and 3 more. Started Dec 2005; status: completed.
02
Drugs
Indeglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-004227-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004227-19.